The sign for the Food and Drug Administration is seen outside headquarters in White Oak, Maryland on July 20, 2020. (Photo by Sarah Silbiger / Getty Images)
ON Newsroom
Retrieved 6:45 PM PT – Friday, November 20, 2020
The FDA granted Emergency Use Author Thorisation for a combination of coronavirus drugs to treat moderately and severely ill patients.
FDA Commissioner Dr. Stephen M. Hayne said the action demonstrates the agency’s efforts to make potential coronavirus treatments available in a timely manner.
On Thursday, the FDA approved a combination of ‘remedazvir’ and the arthritis drug ‘bericitinib’. The study found that the recovery time of COVID-19 from the drug combination was shortened to about a week.
To date, 289 tests have been authorized by the FDA under the EU; These include 224 nuclear tests, 58 antibody tests, and 7 antigen tests.
– US FDA (US_FDA) November 21, 2020
According to the double-blind trial, the chances of surviving even in combination were 35 percent higher than in patients taking ‘remedesivir’ alone.
The FDA has approved the emergency use of rheumatoid arthritis drug bericitinib for hospitalized adults and children in conjunction with rimadesivir for the treatment of suspected or confirmed COVID-19. https://t.co/GVSGz9mdRx pic.twitter.com/esKvNvIg8x
– WebMD (@WebBMD) November 20, 2020
More news: Trump campaign: Americans don’t trust mainstream media election coverage
.
